Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark C Fisher

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Bulletin of the Hospital for Joint Disease (2013)|May 30, 2019
Low-Dose Allopurinol Promotes Greater Serum Urate Lowering in Gout Patients with Chronic Kidney Disease Compared with Normal Kidney FunctionMichael Toprover, Daria B Crittenden, Dodji V Modjinou, et al.
Arthritis Research & Therapy|April 29, 2021
Efficacy and safety of gout flare prophylaxis and therapy use in people with chronic kidney disease: a Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)-initiated literature reviewHuai Leng Pisaniello, Mark C Fisher, Hamish Farquhar, et al.
Journal of Wildlife Diseases|November 18, 2017
Tissue Residue Levels after Immobilization of Rocky Mountain Elk ( Cervus elaphus nelsoni) using a Combination of Nalbuphine, Medetomidine, and Azaperone Antagonized with Naltrexone, Atipamezole, and TolazolineLisa L Wolfe, Pauline Nol, Matthew P McCollum, et al.
Arthritis Research & Therapy|September 11, 2013
Clinical correlations with Porphyromonas gingivalis antibody responses in patients with early rheumatoid arthritisSheila L Arvikar, Deborah S Collier, Mark C Fisher, et al.
BMC Musculoskeletal Disorders|June 2, 2012
Malignancy validation in a United States registry of rheumatoid arthritis patientsMark C Fisher, Victoria Furer, Marc C Hochberg, et al.
The American Journal of Medicine|February 8, 2011
Prevalence of contraindications and prescription of pharmacologic therapies for goutRobert T Keenan, William R O'Brien, Kristen H Lee, et al.
The Journal of Rheumatology|September 17, 2010
Comparative analysis of disease activity measures, use of biologic agents, body mass index, radiographic features, and bone density in psoriatic arthritis and rheumatoid arthritis patients followed in a large U.S. disease registrySoumya M Reddy, Allen P Anandarajah, Mark C Fisher, et al.
The Canadian Journal of Cardiology|May 27, 2020
Colchicine Use and Incident Coronary Artery Disease in Male Patients With GoutBinita Shah, Michael Toprover, Daria B Crittenden, et al.
Arthritis and Rheumatism|September 1, 2007
Protein isoprenylation regulates secretion of matrix metalloproteinase 1 from rheumatoid synovial fibroblasts: effects of statins and farnesyl and geranylgeranyl transferase inhibitorsAryeh M Abeles, Nada Marjanovic, Jean Park, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 5, 2014
A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large US cohortRachael L Gross, Julie S Schwartzman-Morris, Michael Krathen, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Bulletin of the Hospital for Joint Disease (2013)|May 30, 2019
Low-Dose Allopurinol Promotes Greater Serum Urate Lowering in Gout Patients with Chronic Kidney Disease Compared with Normal Kidney FunctionMichael Toprover, Daria B Crittenden, Dodji V Modjinou, et al.
Arthritis Research & Therapy|April 29, 2021
Efficacy and safety of gout flare prophylaxis and therapy use in people with chronic kidney disease: a Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)-initiated literature reviewHuai Leng Pisaniello, Mark C Fisher, Hamish Farquhar, et al.
Journal of Wildlife Diseases|November 18, 2017
Tissue Residue Levels after Immobilization of Rocky Mountain Elk ( Cervus elaphus nelsoni) using a Combination of Nalbuphine, Medetomidine, and Azaperone Antagonized with Naltrexone, Atipamezole, and TolazolineLisa L Wolfe, Pauline Nol, Matthew P McCollum, et al.
Arthritis Research & Therapy|September 11, 2013
Clinical correlations with Porphyromonas gingivalis antibody responses in patients with early rheumatoid arthritisSheila L Arvikar, Deborah S Collier, Mark C Fisher, et al.
BMC Musculoskeletal Disorders|June 2, 2012
Malignancy validation in a United States registry of rheumatoid arthritis patientsMark C Fisher, Victoria Furer, Marc C Hochberg, et al.
The American Journal of Medicine|February 8, 2011
Prevalence of contraindications and prescription of pharmacologic therapies for goutRobert T Keenan, William R O'Brien, Kristen H Lee, et al.
The Journal of Rheumatology|September 17, 2010
Comparative analysis of disease activity measures, use of biologic agents, body mass index, radiographic features, and bone density in psoriatic arthritis and rheumatoid arthritis patients followed in a large U.S. disease registrySoumya M Reddy, Allen P Anandarajah, Mark C Fisher, et al.
The Canadian Journal of Cardiology|May 27, 2020
Colchicine Use and Incident Coronary Artery Disease in Male Patients With GoutBinita Shah, Michael Toprover, Daria B Crittenden, et al.
Arthritis and Rheumatism|September 1, 2007
Protein isoprenylation regulates secretion of matrix metalloproteinase 1 from rheumatoid synovial fibroblasts: effects of statins and farnesyl and geranylgeranyl transferase inhibitorsAryeh M Abeles, Nada Marjanovic, Jean Park, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 5, 2014
A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large US cohortRachael L Gross, Julie S Schwartzman-Morris, Michael Krathen, et al.
Pageof 4